
Hydroxyurea Produces Long-Term Clinical Benefits in Pediatrics With Sickle Cell Anemia
Hydroxyurea, the standard of care disease-modifying treatment for sickle cell anemia (SCA), is effective at sustaining clinical benefits, including reductions in emergency department (ED) visits and hospital days, across years of use in children with SCA, …